Pharmaceuticals
EnGeneIC Announces Publication in Cancer Cell of a Scientific Paper Highlighting the Ability of EDV™ Nanocells to Mount Dual Assault on Cancer Cells
EDV™ Technology Stimulates Both Innate and Adaptive Immune Response and Confers Long-Term Survival Research Paves Way for Treatment of Drug-Resistant, End-Stage Cancers NEW YORK and SYDNEY, March 17, 2020 /PRNewswire/ -- EnGeneIC Limited, a clinical-stage biopharmaceutical company advancing its ...
China SXT Pharmaceuticals, Inc. Announces That It Received a Grant Supported by City Government
TAIZHOU, China, March 16, 2020 /PRNewswire/ -- China SXT Pharmaceuticals, Inc.
(NASDAQ: SXTC
China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2019
BEIJING, March 12, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced its financial results for the fourth quarter and fiscal year of 2019. Fourt...
NDA Filing for Luye Pharma's Antidepressant Drug LY03005 Accepted by the U.S. FDA
SHANGHAI, March. 4, 2020 /PRNewswire/ -- Luye Pharma Group has announced that the U.S. Food and Drug Administration (FDA) has reviewed and accepted the filing of a New Drug Application (NDA) for LY03005, a new chemical drug for the treatment of major depressive disorder. LY03005 is the company's ...
China Biologic Products to Report Fourth Quarter and Fiscal Year 2019 Financial Results
BEIJING, March 3, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the Company plans to release its fourth quarter and fiscal year 2019 fi...
Samsung Biologics and STCube Enter into Development and Manufacturing Agreement for Novel Target Anticancer Drug
SONGDO, South Korea, March 2, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and STCube announced a strategic development and manufacturing service agreement for STT-003 antibody, an anti-cancer drug candidate. Under the agreement, Samsung Biologics will offer a wide range of services from c...
Yuyu Pharma announces review of compliance policies and procedures
SEOUL, South Korea, March 2, 2020 /PRNewswire/ -- Yuyu Pharma (COO Robert Wonsang Yu, KRX 000220) announced today a review of its compliance policies and procedures with the support of the law firm, Kim & Chang. The Kim & Chang project team, consisting of 6 lawyers and 1 expert advisor, implement...
China Pharmaceutical Holdings Co., Ltd. Launched A New Product
HAIKOU CITY, China, March 2, 2020 /PRNewswire/ -- China Pharmaceutical Holdings Limited (NYSE American: CPHI) ("China Pharma" or "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced that its subsidiary, Hainan ...
Samsung Biologics Confirms 'No Impact' of COVID-19 with Business Continuity Plan in Effect
SONGDO, South Korea, Feb. 24, 2020 /PRNewswire/ -- Samsung Biologics has been monitoring the COVID-19 situation closely since the initial outbreak in late January and taking proactive measures company-wide to ensure a safe working environment and continuous business operations. The company confi...
WuXi Diagnostics' integrated testing solution for COVID-19 epidemiological investigation and diagnosis
SHANGHAI, Feb. 27, 2020 /PRNewswire/ -- WuXi Diagnostics has successfully developed a series of COVID-19 detection products, including2019-nCoV IgM Detection kit (Enzyme-linked Immunoassay, ELISA), 2019-nCoV IgM/IgG Detection Kit (Enzyme-linked Immunoassay, ELISA) and 2019-nCoV Nucleic Acid Detec...
Ascentage Pharma Announces Approval for the Phase Ib/II Clinical Trial of APG-1387 in Combination with Chemotherapy for the Treatment of Advanced Pancreatic Cancer in China
SUZHOU, China and ROCKVILLE, MD., Feb. 24, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company has receive...
WuXi Biologics Congratulates Immutep on Positive Interim Data for IMP-321
SHANGHAI, Feb. 23, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, congratulates its strategic partner Immutep, a biotechnology comp...
VolitionRx Limited Announces Full Fiscal Year 2019 Financial Results and Business Update
AUSTIN, Texas, Feb. 20, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the full fiscal year endedDecember 31, 2019. Volition management will host a conference call tomorrow,February 21, at 8:30 a.m. U.S. Easte...
StoneWise AI-driven Drug Discovery Platform: Investigation and Repurpose of Nucleoside-based RNA Polymerase Inhibitors and Their Potential Use in COVID-19 Infection Treatment
BEIJING, Feb. 20, 2020 /PRNewswire/ -- In a campaign to screen drugs for the treatment of COVID-19, the disease caused by SARS-CoV-2, StoneWise, a company specialized in applying artificial intelligence to innovative drug design solutions for innovative drug R&D enterprises and institutions, has ...
111 Partners with Financial Institutions in Battle Against Coronavirus
SHANGHAI, Feb. 20, 2020 /PRNewswire/ -- 111, Inc. (NASDAQ: YI, "111" or the "Company") has announced that it will leverage its knowhow and technology in the battle against the novel coronavirus (COVID-19) public health crisis, through partnerships with some ofChina's leading financial institution...
VolitionRx Limited Schedules Full Year 2019 Earnings Conference Call and Business Update
AUSTIN, Texas, Feb. 18, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call onFriday, February 21 at 8:30 a.m. Eastern time to discuss its financial and operating results for the fourth quarter and full year 2019, in conjunctio...
Ally Bridge Group Leads US$70 million Investments in Two Israeli Life Science Companies over the Last 2 Months
TEL AVIV, Israel, HONG KONG and NEW YORK, Feb. 18, 2020 /PRNewswire/ — Ally Bridge Group ("ABG"), a leading global life science investment group, has announced that it recently ledUS$70 million investments in two Israeli life science companies over the last 2 months. Each of the two companies is ...
Volition Unveils Its Epigenetic Toolbox
AUSTIN, Texas, Feb. 18, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that research on its Nu.Q(TM) Capture program has led to the development of a suite of novel epigenetic tools building on the breakthroughs announced last month on its assay platform...
Immuron reports diarrhea no.1 health issue for Americans on vacation
NEW YORK, Feb. 12, 2020 /PRNewswire/ -- Diarrhea remains the top health issue
facing Americans traveling to high risk countries, affecting 30 to 70 per
cent of travelers depending upon their destination, according to
biopharmaceutical company Immuron Limited[1], [2].
GC Pharma Reports Full Year 2019 Results
All consolidated entities revenues grew plus compared to prior year YONGIN, South Korea, Feb. 12, 2020 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the year ended31 December 201...
Week's Top Stories
Most Reposted
Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 305 media titles]
2024-11-20 13:29Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 301 media titles]
2024-11-21 10:30Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 299 media titles]
2024-11-20 16:30Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
[Picked up by 296 media titles]
2024-11-15 15:25